A heart-device startup braves the IPO waters
(UPDATED: See below.)
It’s been a rough few months for life-science IPOs, what with all the collapsed offerings and, often enough, miserable post-offering performance for those startups that have managed to inch their way across the finish line.
Yet the lure of the public markets remains strong, even… Continue Reading
Life sciences briefing: Thursday, Feb. 28, 2008
TODAY’S HEADLINES:
RNAi developer PhaseRx gets $4M of a pledged $19M (Seattle Times)
TyRx Pharma, drug-device combo maker, raises $25M (release)
Agennix aims at $40M for cancer drugs (VentureWire)
Starr Life Sciences goes after $1.6M for small-animal vital-signs scanner (VW)
CardioNet sets IPO terms, aims to raise $96M (IPOhome)
RNAi developer… Continue Reading
Life sciences briefing: Monday, Aug. 20, 2007
(UPDATED at 7:10pm PT: See below.)
Featured companies: NeurAxon, VytronUS, Avila Therapeutics, CardioNet, Ventana Medical Systems, CytoLogix, PlaCor
NeurAxon raises $32M for pain drugs — You have to hand it to Waltham, Mass.-based NeurAxon — the company certainly knows how to keep itself in the news. Today, it announced… Continue Reading
CardioNet, wireless heart monitoring company, raises whopping $110M
San Diego-based CardioNet, Inc., a provider of wireless mobile heart monitoring technology, said it has raised $110 million in private financing from undisclosed hedge funds, the largest venture round in the medical sector since 2000.
CardioNet has raised close to $200 million in private debt and… Continue Reading